US5376645A
(en)
*
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
US5262404A
(en)
*
|
1990-02-15 |
1993-11-16 |
The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation |
Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
|
EP0710673A3
(en)
|
1990-05-21 |
1996-08-07 |
Toppan Printing Co Ltd |
Derivatives of cyclodextrins
|
JP2556236B2
(ja)
*
|
1991-08-29 |
1996-11-20 |
田辺製薬株式会社 |
β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
|
EP0610295A1
(en)
*
|
1991-10-16 |
1994-08-17 |
Schering Corporation |
Lipophilic oligosaccharide antibiotic salt compositions
|
DE4204315A1
(de)
*
|
1992-02-13 |
1993-08-19 |
Consortium Elektrochem Ind |
Cyclodextringlycoside und verfahren zu ihrer herstellung
|
US5403828A
(en)
*
|
1992-08-13 |
1995-04-04 |
American Maize-Products Company |
Purification of cyclodextrin complexes
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
DE4309579C3
(de)
*
|
1993-03-24 |
2000-01-27 |
Sanol Arznei Schwarz Gmbh |
Pharmazeutische Zusammensetzung in Form einer Packung
|
DE4313408A1
(de)
*
|
1993-04-23 |
1994-10-27 |
Boehringer Mannheim Gmbh |
Cyclodextrin-Biocid-Komplex
|
HU213200B
(en)
*
|
1993-05-12 |
1997-03-28 |
Chinoin Gyogyszer Es Vegyeszet |
The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
|
RU2135176C1
(ru)
*
|
1993-12-14 |
1999-08-27 |
Эли Лилли Энд Компани |
Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
|
US5443824A
(en)
*
|
1994-03-14 |
1995-08-22 |
Piacquadio; Daniel J. |
Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
|
DE4429229A1
(de)
*
|
1994-08-18 |
1996-02-22 |
Consortium Elektrochem Ind |
Cyclodextrinderivate mit mindestens einem stickstoffhaltigen Heterozyklus, ihre Herstellung und Verwendung
|
EP0709099A3
(en)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
Aqueous suspension for nasal administration containing cyclodextrin
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
BE1008978A5
(fr)
*
|
1994-12-27 |
1996-10-01 |
Solvay |
Adjuvants pour vaccins.
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
DE19505263A1
(de)
*
|
1995-02-16 |
1996-08-22 |
Consortium Elektrochem Ind |
Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
|
AU5774796A
(en)
*
|
1995-06-13 |
1997-01-09 |
Dyer, Alison Margaret |
Pharmaceutical compositions containing lornoxicam and cyclod extrin
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
HUT75956A
(en)
*
|
1995-11-29 |
1997-05-28 |
Cyclolab |
Pharmaceutical composition containing thyroxine
|
GB9605705D0
(en)
|
1996-03-19 |
1996-05-22 |
Pfizer Ltd |
Therapeutic agents
|
DE69733664T3
(de)
|
1996-04-19 |
2011-04-14 |
Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles |
Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
DE69740095D1
(de)
*
|
1996-11-05 |
2011-02-17 |
Childrens Medical Center |
Thalidomide und Dexamethason für die Behandlung von Tumors
|
KR100435426B1
(ko)
*
|
1996-11-29 |
2004-08-16 |
주식회사 포스코 |
구조 이성질체의 분리에 유용한 6-디메틸옥틸실릴-2,3-디에틸-베타-시클로덱스트린 및 그 제조방법
|
KR100411289B1
(ko)
*
|
1996-11-29 |
2004-02-14 |
주식회사 포스코 |
회전장애 이성질체의 분리에 유용한 6-알릴디메틸실릴-2,3-디에 틸-베타-시클로덱스트린 및 그 제조방법
|
DE19713092A1
(de)
*
|
1997-03-27 |
1998-10-01 |
Wacker Chemie Gmbh |
Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
ATE253941T1
(de)
*
|
1997-06-13 |
2003-11-15 |
Cydex Inc |
Zusammensetzung mit erhöhter lagerstabilität enthaltend cyclodextrin und wirkstoffe oder wirkstoff-vorstufen, die in wasserunlösliche komponenten zersetzt werden
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
DK0889056T3
(da)
*
|
1997-07-01 |
2006-07-17 |
Pfizer Prod Inc |
Process for making a cyclodextrin
|
US6391862B1
(en)
*
|
1997-10-14 |
2002-05-21 |
The Texas A&M University System |
Chiral resolving agents for enantioseparations
|
NZ505951A
(en)
*
|
1998-02-23 |
2003-02-28 |
Cyclops Ehf |
A method for enhancing the complexation efficiency of a heterocyclic drug with cyclodextrin, by subjecting the heterocycloc drug to chemically reversible ring-opening
|
US6699849B1
(en)
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
US6048736A
(en)
*
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
US6673828B1
(en)
*
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
DE19825486C2
(de)
|
1998-06-08 |
2000-07-06 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit supramolekularen Hohlraummolekülen, Verfahren zu deren Herstellung und deren Verwendung
|
NZ330726A
(en)
*
|
1998-06-18 |
2000-10-27 |
Dec Res |
Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
|
US20040152664A1
(en)
*
|
1998-09-02 |
2004-08-05 |
Allergan, Inc. |
Prednisolone compositions
|
US20020198174A1
(en)
*
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
EP1109581A1
(en)
|
1998-09-02 |
2001-06-27 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
GEP20043214B
(en)
|
1999-01-21 |
2004-04-26 |
Bristol Myers Squibb Company Us |
Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7- Beta – Cyclodextrin or 2-Hydroxypropyl- Beta – Cyclodextrina and Pharmaceutical Compositions Containing the Same
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
GB9915231D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
DE19939662A1
(de)
|
1999-08-20 |
2001-02-22 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit Hohlraumverbindungen, Verfahren zur deren Herstellung und deren Verwendung
|
GB9921958D0
(en)
*
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
|
GB9921954D0
(en)
*
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
MXPA02006537A
(es)
*
|
1999-12-28 |
2002-12-09 |
Kimberly Clark Co |
Polimeros superabsorbentes.
|
US6689378B1
(en)
|
1999-12-28 |
2004-02-10 |
Kimberly-Clark Worldwide, Inc. |
Cyclodextrins covalently bound to polysaccharides
|
US6677256B1
(en)
|
1999-12-28 |
2004-01-13 |
Kimberly-Clark Worldwide, Inc. |
Fibrous materials containing activating agents for making superabsorbent polymers
|
SK282717B6
(sk)
*
|
2000-03-10 |
2002-11-06 |
�Stav Experiment�Lnej Farmakol�Gie Sav |
Spôsob prípravy ultravysokomolekulových hyalurónanov
|
US20020022627A1
(en)
*
|
2000-03-31 |
2002-02-21 |
Dannenberg Andrew J. |
Inhibition of cyclooxygenase-2activity
|
CA2406823A1
(en)
*
|
2000-04-28 |
2001-11-08 |
Lawrence John Penkler |
Amphiphilic macrocyclic derivatives and their analogues
|
SI1278549T1
(sl)
*
|
2000-05-02 |
2009-04-30 |
Theravance Inc |
Sestavek, ki vsebuje ciklodekstrin in glikopeptidni antibiotik
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
EP1284974B1
(en)
|
2000-05-26 |
2004-03-03 |
Pfizer Limited |
Triazolyl tropane derivatives as ccr5 modulators
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
US20040198706A1
(en)
*
|
2003-03-11 |
2004-10-07 |
Carrara Dario Norberto R. |
Methods and formulations for transdermal or transmucosal application of active agents
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
US20070225379A1
(en)
*
|
2001-08-03 |
2007-09-27 |
Carrara Dario Norberto R |
Transdermal delivery of systemically active central nervous system drugs
|
AU8206401A
(en)
*
|
2000-08-03 |
2002-02-18 |
Antares Pharma Ipl Ag |
Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
|
US7198801B2
(en)
*
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
PE20020300A1
(es)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
US7812169B2
(en)
*
|
2000-11-30 |
2010-10-12 |
The Children's Medical Center Corporation |
Method of synthesis of 4-amino-thalidomide enantiomers
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
JP2005503446A
(ja)
|
2001-01-11 |
2005-02-03 |
イーストマン ケミカル カンパニー |
シクロデキストリンスルホネート、ゲスト包接錯体、その製造方法及び関連物質
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
PL217629B1
(pl)
|
2001-04-10 |
2014-08-29 |
Pfizer |
Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie
|
BR0102252B1
(pt)
*
|
2001-04-10 |
2013-10-22 |
|
Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
|
JP2004531537A
(ja)
*
|
2001-05-01 |
2004-10-14 |
ファイザー・プロダクツ・インク |
一様な薬剤分布と効力を有する低用量製薬組成物の製造方法
|
UY27304A1
(es)
|
2001-05-24 |
2002-12-31 |
Avanir Pharmaceuticals |
Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
EP1269994A3
(en)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
AU2002363959B2
(en)
*
|
2001-12-03 |
2007-12-13 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
BR0307332A
(pt)
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
JP4583761B2
(ja)
|
2002-02-11 |
2010-11-17 |
ファイザー・インク |
Pde4阻害剤として有用なニコチンアミド誘導体
|
US20030164219A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Joerg Brahm |
Headliner/duct assembly and welding process therefor
|
AU2003213210A1
(en)
*
|
2002-02-22 |
2003-09-09 |
Pharmacia Corporation |
Ophthalmic formulation with gum system
|
BR0307898A
(pt)
*
|
2002-02-22 |
2004-12-07 |
Pharmacia Corp |
Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
KR100451485B1
(ko)
*
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
DE10215942A1
(de)
*
|
2002-04-11 |
2003-10-23 |
Bayer Ag |
Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
US6869939B2
(en)
*
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
EP1556033A4
(en)
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
DE60331537D1
(de)
|
2002-05-17 |
2010-04-15 |
Celgene Corp |
Kombinationen zur behandlung von multiplem myelom
|
US6818662B2
(en)
*
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
UA79984C2
(en)
*
|
2002-08-20 |
2007-08-10 |
Bristol Myers Squibb Co |
Preparation on the basis of aripiprazole complex and use thereof
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
US6884790B2
(en)
*
|
2002-09-09 |
2005-04-26 |
Josef Pitha |
Verifiable absorption drug delivery form based on cyclodextrins
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
JP2006503047A
(ja)
*
|
2002-09-13 |
2006-01-26 |
サイデックス・インコーポレイテッド |
誘導シクロデキストリンにより安定化された水性フィル組成物を含有するカプセル
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
US20040053895A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
CA2501936A1
(en)
*
|
2002-10-15 |
2004-04-29 |
Celgene Corporation |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
US20040087558A1
(en)
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
US7001893B2
(en)
*
|
2002-10-28 |
2006-02-21 |
Council Of Scientific And Industrial Research |
Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
CN1735412A
(zh)
|
2002-11-06 |
2006-02-15 |
细胞基因公司 |
利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物
|
US20050026877A1
(en)
*
|
2002-12-03 |
2005-02-03 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
DE60332387D1
(de)
|
2002-12-13 |
2010-06-10 |
Warner Lambert Co |
Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
US7166575B2
(en)
*
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
US7229966B2
(en)
*
|
2002-12-17 |
2007-06-12 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
CA2510199A1
(en)
*
|
2002-12-17 |
2004-07-08 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
|
US7186692B2
(en)
*
|
2002-12-17 |
2007-03-06 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
CA2513331A1
(en)
*
|
2003-01-14 |
2004-08-05 |
Teva Pharmaceutical Industries Ltd |
Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
|
BRPI0406745A
(pt)
*
|
2003-01-14 |
2005-12-20 |
Teva Pharma |
Formulações parenterais de peptìdeos para o tratamento de lupus eritematoso sistêmico
|
EP1460064A1
(en)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide derivatives useful as beta-2 agonists
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
US20050020546A1
(en)
*
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
AU2004263830B2
(en)
|
2003-06-13 |
2008-12-18 |
Alnylam Pharmaceuticals, Inc. |
Double-stranded ribonucleic acid with increased effectiveness in an organism
|
WO2005023257A1
(en)
|
2003-09-03 |
2005-03-17 |
Glaxo Group Limited |
Novel process, salts, compositions and use
|
AP2184A
(en)
|
2003-09-03 |
2010-12-02 |
Pfizer |
Benzimidazolone compounds having 5-HT4 receptor agonistic activity.
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
WO2005023308A1
(en)
*
|
2003-09-05 |
2005-03-17 |
Maxygen Holdings Ltd. |
Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
|
CN1849153A
(zh)
|
2003-09-12 |
2006-10-18 |
辉瑞大药厂 |
含有α-2-δ配体和5-羟色胺/去甲肾上腺素重摄取抑制剂的组合物
|
ES2295924T3
(es)
|
2003-10-03 |
2008-04-16 |
Pfizer, Inc. |
Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.
|
PL1670433T3
(pl)
|
2003-10-10 |
2013-03-29 |
Ferring Bv |
Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
AU2004288714A1
(en)
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
|
NZ547389A
(en)
|
2003-11-21 |
2009-11-27 |
Combinatorx Inc |
Combinations of a compound such as ibudilast and a corticosteroid for the treatment of inflammatory disorders
|
WO2005055952A2
(en)
*
|
2003-12-08 |
2005-06-23 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Synergistic anti-cancer compositions
|
DK1691811T3
(da)
|
2003-12-11 |
2014-10-20 |
Sunovion Pharmaceuticals Inc |
Kombination af et sedativ og en neurotransmittermodulator og fremgangsmåder til forbedring af søvnkvaliteten og behandling af depression
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
US20070020299A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
RU2390330C2
(ru)
*
|
2003-12-31 |
2010-05-27 |
Сайдекс, Инк. |
Ингаляционная препаративная форма, содержащая простой сульфоалкиловый эфир гамма-циклодекстрина и кортикостероид
|
US7449462B2
(en)
|
2004-01-22 |
2008-11-11 |
Pfizer, Inc. |
Triazole derivatives which inhibit vasopressin antagonistic activity
|
RS50561B
(sr)
|
2004-01-22 |
2010-05-07 |
Pfizer Inc. |
Derivati sulfonamida za lečenje bolesti
|
DK1708992T3
(da)
|
2004-01-22 |
2007-11-05 |
Pfizer |
Sulfonamidderivater til behandling af sygdomme
|
WO2005082425A1
(en)
|
2004-02-24 |
2005-09-09 |
The General Hospital Corporation |
Catalytic radiofluorination
|
WO2005088655A1
(en)
*
|
2004-03-12 |
2005-09-22 |
The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
A magnetoresistive medium
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
EP1735284A1
(en)
|
2004-03-18 |
2006-12-27 |
Pfizer Limited |
N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
|
EP2505200A1
(en)
|
2004-03-22 |
2012-10-03 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
|
BRPI0507877A
(pt)
|
2004-03-23 |
2007-07-24 |
Pfizer |
derivados de formamida, composição farmacêutica, uso dos mesmos e combinação
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
EP1744749A4
(en)
*
|
2004-04-14 |
2009-04-22 |
Celgene Corp |
METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES
|
BRPI0418743A
(pt)
*
|
2004-04-14 |
2007-09-18 |
Celgene Corp |
métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
|
SG185306A1
(en)
|
2004-04-15 |
2012-11-29 |
Onyx Therapeutics Inc |
Compounds for proteasome enzyme inhibition
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
MXPA06012240A
(es)
|
2004-04-23 |
2007-01-31 |
Cydex Inc |
Formulacion para inhalador de polvo seco que contiene eter sulfoalquilico-ciclodextrina.
|
JP4185154B2
(ja)
|
2004-04-30 |
2008-11-26 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
中枢神経系障害治療用の置換モルホリン化合物
|
EP1750776A2
(en)
|
2004-04-30 |
2007-02-14 |
Alnylam Pharmaceuticals Inc. |
Oligonucleotides comprising a c5-modified pyrimidine
|
KR20070009671A
(ko)
*
|
2004-05-06 |
2007-01-18 |
사이덱스 인크 |
세르트랄린 및 술포알킬 에테르 시클로덱스트린을 함유하는맛 마스킹된 제제
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
US8088741B2
(en)
*
|
2004-05-10 |
2012-01-03 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
EP1595881A1
(en)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
EP1758891A2
(en)
|
2004-06-15 |
2007-03-07 |
Pfizer Japan Inc. |
Benzimidazolone carboxylic acid derivatives
|
WO2006007412A2
(en)
*
|
2004-06-16 |
2006-01-19 |
Nastech Pharmaceutical Company Inc. |
Peptide yy formulations having increased stability and resistance to microbial agents
|
PT1768966E
(pt)
|
2004-06-17 |
2012-05-23 |
Infinity Discovery Inc |
Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação
|
AP2326A
(en)
|
2004-08-12 |
2011-11-24 |
Pfizer |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
|
PL1786785T3
(pl)
|
2004-08-26 |
2010-08-31 |
Pfizer |
Enancjomerycznie czyste związki aminoheteroarylowe jako kinazy białkowe
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
CA2579291C
(en)
*
|
2004-09-03 |
2011-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
|
EP1809618B1
(en)
|
2004-09-21 |
2013-07-17 |
Marshall Edwards, Inc. |
Chroman derivatives, medicaments and use in therapy
|
ATE532777T1
(de)
|
2004-09-21 |
2011-11-15 |
Marshall Edwards Inc |
Substituierte chromanderivate, medikamente und anwendungen in der therapie
|
US8080675B2
(en)
|
2004-09-21 |
2011-12-20 |
Marshall Edwards, Inc. |
Chroman derivatives, medicaments and use in therapy
|
US20060078955A1
(en)
*
|
2004-10-13 |
2006-04-13 |
Lin-Zhi International |
Method for retrieving delta9-THC from oral fluid
|
RU2349334C2
(ru)
*
|
2004-10-26 |
2009-03-20 |
Виктор Олександровыч Рыбчук |
Лекарственное средство седативного и спазмолитического действия и способ его изготовления (варианты)
|
JP2008518924A
(ja)
*
|
2004-10-28 |
2008-06-05 |
セルジーン・コーポレーション |
中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物
|
MX2007005290A
(es)
|
2004-11-02 |
2007-07-09 |
Pfizer |
Derivados de sulfonilbencimidazol.
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
WO2006052922A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Eastman Chemical Company |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
WO2006052921A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Eastman Chemical Company |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
ATE499109T1
(de)
*
|
2004-12-07 |
2011-03-15 |
Proteolix Inc |
Zusammensetzung zur proteasomhemmung
|
US20060128654A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
US20060128653A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
DE102004060927B3
(de)
*
|
2004-12-17 |
2006-02-16 |
Schwan-Stabilo Schwanhäusser Gmbh & Co. Kg |
Behälter für mindestens einen länglichen Gegenstand
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
TW200738252A
(en)
*
|
2005-02-16 |
2007-10-16 |
Alza Corp |
Apparatus and method for transdermal delivery of Epoetin-based agents
|
EP1848437A4
(en)
*
|
2005-02-18 |
2012-04-25 |
Surface Logix Inc |
METHOD FOR PRODUCING PHARMACOKINETIC IMPROVED COMPOUNDS WITH FUNCTIONAL RESTORATIONS OR GROUPS AND PHARMACEUTICAL COMPOSITIONS WITH THESE COMPOUNDS
|
CN102351862A
(zh)
*
|
2005-02-18 |
2012-02-15 |
表面线段公司 |
药动学改善的化合物
|
US8703099B2
(en)
|
2005-02-24 |
2014-04-22 |
Dr Pharma Nova, Llc |
Registry method and control system for DEA schedule II-V medicines
|
CN101160285A
(zh)
|
2005-03-17 |
2008-04-09 |
辉瑞大药厂 |
适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物
|
US7618972B2
(en)
|
2005-03-21 |
2009-11-17 |
Pfizer Inc |
Substituted triazole derivatives as oxytocin antagonists
|
US20090298802A1
(en)
|
2005-03-30 |
2009-12-03 |
Sequeira Joel A |
Pharmaceutical Compositions
|
WO2006113479A2
(en)
*
|
2005-04-15 |
2006-10-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy
|
EP1874331B1
(en)
|
2005-04-19 |
2014-09-03 |
Kings College London |
Use of bip against bone loss and osteoporosis
|
CN101203217A
(zh)
*
|
2005-04-24 |
2008-06-18 |
惠氏公司 |
调节膀胱功能的方法
|
EA200702235A1
(ru)
|
2005-05-04 |
2008-04-28 |
Пфайзер Лимитед |
Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
|
WO2006124726A2
(en)
*
|
2005-05-12 |
2006-11-23 |
The General Hospital Corporation |
Novel biotinylated compositions
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
WO2006125642A1
(en)
*
|
2005-05-27 |
2006-11-30 |
Antares Pharma Ipl Ag |
Methods and apparatus for transdermal or transmucosal application of testosterone
|
CA2611917A1
(en)
*
|
2005-06-13 |
2006-12-21 |
Takeda Pharmaceutical Company Limited |
Injection
|
RU2008101420A
(ru)
*
|
2005-06-13 |
2009-07-20 |
Карджилл, Инкорпорейтед (Us) |
Циклодекстриновые комплексы включения и способы их получения
|
KR20080023684A
(ko)
*
|
2005-06-13 |
2008-03-14 |
카아길, 인코포레이팃드 |
시클로덱스트린 포접 착물 및 이의 제조 방법
|
ATE456557T1
(de)
|
2005-06-15 |
2010-02-15 |
Pfizer Ltd |
Substituierte arylpyrazole zur verwendung gegen parasiten
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
US20060287301A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mcnair Douglas |
Novel formulations for phenothiazines, including fluphenazine and its derivatives
|
AU2006265019B2
(en)
|
2005-06-30 |
2011-10-13 |
Celgene Corporation |
Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds
|
US20070010487A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
US20070010485A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
US20070009531A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
|
WO2007008496A1
(en)
*
|
2005-07-06 |
2007-01-18 |
Kanisa Pharmaceuticals, Inc. |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
US20070010465A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
|
US20070010486A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
AR054849A1
(es)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
CA2822094C
(en)
|
2005-08-31 |
2015-10-27 |
Celgene Corporation |
Isoindole-imide compounds and compositions comprising and methods of using the same
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
US7744904B1
(en)
*
|
2005-09-26 |
2010-06-29 |
B.B. Scientific L.L.C. |
Stabilization of Clostridium botulinum neurotoxin complex
|
JP5284096B2
(ja)
|
2005-09-30 |
2013-09-11 |
ルンドベック エルエルシー |
新規非経口カルバマゼピン製剤
|
AU2013200204B9
(en)
*
|
2005-09-30 |
2015-03-05 |
Lundbeck Llc |
Novel parenteral carbamazepine formulation
|
US20100204178A1
(en)
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
US7629331B2
(en)
|
2005-10-26 |
2009-12-08 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
MX348982B
(es)
|
2005-10-26 |
2017-07-06 |
Cydex Pharmaceuticals Inc |
Composiciones de eter sulfoalquilico-ciclodextrina y metodos de preparacion de las mismas.
|
AU2011204957B2
(en)
*
|
2005-10-26 |
2013-12-05 |
Cydex Pharmaceuticals, Inc |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
CN100503647C
(zh)
|
2005-11-02 |
2009-06-24 |
南京师范大学 |
羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
|
PL2623113T3
(pl)
|
2005-11-09 |
2018-05-30 |
Onyx Therapeutics, Inc. |
Związek do hamowania enzymu
|
BRPI0618653A2
(pt)
*
|
2005-11-15 |
2011-09-06 |
Baxter Int |
composições compreendendo inibidores da lipoxigenase e ciclodextrina
|
US7658913B2
(en)
*
|
2005-11-28 |
2010-02-09 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
EP1954292B1
(en)
*
|
2005-11-28 |
2014-05-07 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
WO2007062266A2
(en)
|
2005-11-28 |
2007-05-31 |
Marinus Pharmaceuticals |
Ganaxolone formulations and methods for the making and use thereof
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
US20070232537A1
(en)
*
|
2005-12-19 |
2007-10-04 |
Nastech Pharmaceutical Company Inc. |
Intranasal pyy formulations with improved transmucosal pharmacokinetics
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
CA2642579A1
(en)
*
|
2006-02-15 |
2007-08-23 |
Tika Lakemedel Ab |
Sterilization of corticosteroids with reduced mass loss
|
AR060088A1
(es)
*
|
2006-03-24 |
2008-05-21 |
Wyeth Corp |
Metodos para tratar trastornos cognitivos y otros afines
|
CA2644662A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
New therapeutic combinations for the treatment of depression
|
WO2007112000A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Treatment of pain
|
PE20080172A1
(es)
*
|
2006-03-24 |
2008-04-21 |
Wyeth Corp |
Compuestos dihidrobenzofuranil alcanamida como moduladores del receptor 5-ht2c
|
EP1998782A2
(en)
*
|
2006-03-24 |
2008-12-10 |
Wyeth a Corporation of the State of Delaware |
Methods for modulating bladder function
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
AU2007237903A1
(en)
*
|
2006-04-18 |
2007-10-25 |
Ekr Therapeutics, Inc. |
Pre-mixed, ready-to-use iv bolus compositions and methods of use
|
CA2646667C
(en)
*
|
2006-04-21 |
2014-03-11 |
Antares Pharma Ipl Ag |
Methods of treating hot flashes with formulations for transdermal or transmucosal application
|
WO2007136640A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
CN100374468C
(zh)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
水溶性磺烷基醚-β-环糊精的合成工艺
|
MX2008015775A
(es)
|
2006-06-12 |
2009-04-17 |
Sunesis Pharmaceuticals Inc |
Compuestos y composiciones para tratamiento de cancer.
|
EP2027136A4
(en)
*
|
2006-06-13 |
2011-08-03 |
Cargill Inc |
Large part cyclicxtrin inclusion complexes and method for their preparation
|
DK2041158T3
(da)
*
|
2006-06-19 |
2013-06-24 |
Onyx Therapeutics Inc |
Peptid-epoxidketoner til proteasom inhibering
|
CA2656613A1
(en)
*
|
2006-07-03 |
2008-01-10 |
Genmab A/S |
Prevention of rash in patients undergoing anti-egfr therapy
|
AR061889A1
(es)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
Proceso mejorado para la preparacion de voriconazol
|
GB2453475B
(en)
|
2006-07-25 |
2011-01-19 |
Secr Defence |
Live vaccine strain
|
WO2008016702A2
(en)
|
2006-08-02 |
2008-02-07 |
Sunesis Pharmaceuticals, Inc. |
Combined use of (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1(2-thiazolyl)-1,8-naphthyridine-3-carboxylic
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
US8377971B2
(en)
|
2006-08-03 |
2013-02-19 |
Trustees Of Tufts College |
Non-flushing niacin analogues, and methods of use thereof
|
JP2010501591A
(ja)
|
2006-08-23 |
2010-01-21 |
インテレクト・ニューロサイエンシズ・インコーポレーテッド |
3−(3−インドリル)プロピオン酸カルシウム塩およびそれから3−(3−インドリル)プロピオン酸の遊離酸を作る方法
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
CN100411688C
(zh)
*
|
2006-09-12 |
2008-08-20 |
南京师范大学 |
含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
|
CN100486645C
(zh)
*
|
2006-09-12 |
2009-05-13 |
南京师范大学 |
含有环糊精紫杉醇包合物的药物组合物及其制备方法
|
US8278355B2
(en)
|
2006-09-12 |
2012-10-02 |
Therexcell Pharma Inc. |
Isovaline for treatment of pain
|
WO2008031439A2
(en)
|
2006-09-15 |
2008-03-20 |
Stevia Aps |
Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol
|
SI2061458T1
(sl)
*
|
2006-09-15 |
2015-04-30 |
Regents Of The University Of Minnesota |
Sestavki topiramata in metode za njihovo uporabo
|
US20090239942A1
(en)
*
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
US8466166B2
(en)
|
2006-09-21 |
2013-06-18 |
Raqualia Pharma Inc. |
Benzimidazole derivatives as selective acid pump inhibitors
|
HUE035308T2
(en)
|
2006-09-26 |
2018-05-02 |
Celgene Corp |
5-substituted quinazoline derivatives as anticancer agents
|
AU2007308145A1
(en)
|
2006-10-12 |
2008-04-17 |
Wyeth |
Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
|
AP2780A
(en)
|
2006-10-18 |
2013-09-30 |
Pfizer Prod Inc |
Biaryl ether urea compounds
|
CA2666539A1
(en)
|
2006-10-23 |
2008-05-02 |
Pfizer Inc. |
Substituted phenylmethyl bicyclocarboxyamide compounds
|
JP5401319B2
(ja)
|
2006-11-03 |
2014-01-29 |
ワイス・エルエルシー |
細胞培養における解糖阻害物質
|
JP2010510311A
(ja)
*
|
2006-11-21 |
2010-04-02 |
ノバルティス アーゲー |
ベンゾジアゼピン構造のrsv阻害剤を含む安定な非経腸製剤
|
WO2008065142A1
(en)
*
|
2006-11-29 |
2008-06-05 |
N.V. Organon |
Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
|
WO2008067991A2
(en)
*
|
2006-12-08 |
2008-06-12 |
Antares Pharma Ipl Ag |
Skin-friendly drug complexes for transdermal administration
|
JP2010514794A
(ja)
*
|
2006-12-27 |
2010-05-06 |
カーギル インコーポレイテッド |
シクロデキストリン封入複合体および該複合体を調製する方法
|
ATE530188T1
(de)
*
|
2007-03-02 |
2011-11-15 |
Univ Wollongong |
Zusammensetzungen und verfahren zur abgabe von mitteln gegen krebs
|
US9012180B2
(en)
|
2007-03-02 |
2015-04-21 |
Wyeth Llc |
Use of copper and glutamate in cell culture for production of polypeptides
|
WO2011084703A2
(en)
|
2009-12-21 |
2011-07-14 |
Advanced Liquid Logic, Inc. |
Enzyme assays on a droplet actuator
|
EP3766493B1
(en)
|
2007-04-27 |
2023-08-23 |
CyDex Pharmaceuticals, Inc. |
Method for improving the stability of clopidogrel using sulfoalkyl ether cyclodextrin
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
US20080283693A1
(en)
*
|
2007-05-15 |
2008-11-20 |
Evans Michael J F |
Propulsion apparatus and system
|
CA2689016C
(en)
|
2007-05-25 |
2014-08-12 |
Ipsen Pharma S.A.S. |
Melanocortin receptor ligands modified with hydantoin
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
TWI428132B
(zh)
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
癌症化療效果之強化
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
WO2009018326A2
(en)
*
|
2007-07-31 |
2009-02-05 |
Limerick Biopharma, Inc. |
Soluble pyrone analogs methods and compositions
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
CA2697495C
(en)
|
2007-09-05 |
2013-02-05 |
Pfizer Limited |
Xinafoate salt of n4-[(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
CN104211684A
(zh)
|
2007-09-26 |
2014-12-17 |
细胞基因公司 |
6-、7-或8-取代的喹唑啉酮衍生物、含有它的组合物及其使用方法
|
KR20170125413A
(ko)
|
2007-10-04 |
2017-11-14 |
오닉스 세라퓨틱스, 인크. |
결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
|
CN103720701A
(zh)
*
|
2007-10-22 |
2014-04-16 |
逊尼希思制药公司 |
在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
US20090232796A1
(en)
*
|
2008-02-20 |
2009-09-17 |
Corral Laura G |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
WO2009107877A1
(en)
*
|
2008-02-28 |
2009-09-03 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical composition
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
US7635773B2
(en)
*
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
WO2009134396A2
(en)
*
|
2008-04-30 |
2009-11-05 |
Neutron Row |
Methods of using corticotropin-releasing factor for the treatment of cancer
|
WO2009137611A2
(en)
*
|
2008-05-06 |
2009-11-12 |
Board Of Regents, The University Of Texas System |
Treatment of pulmonary fungal infection with voriconazole via inhalation
|
US20110144202A1
(en)
*
|
2008-06-16 |
2011-06-16 |
Uwe Marx |
Concentrated oxaliplatin solution and its method of preparation
|
WO2010014617A1
(en)
*
|
2008-07-28 |
2010-02-04 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
ATE542813T1
(de)
|
2008-08-06 |
2012-02-15 |
Pfizer |
6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
|
CA2738328A1
(en)
|
2008-08-29 |
2010-03-04 |
Novogen Research Pty Ltd |
Immunomodulating activities
|
EP2163253B1
(en)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
|
WO2010048298A1
(en)
|
2008-10-21 |
2010-04-29 |
Proteolix, Inc. |
Combination therapy with peptide epoxyketones
|
CN102596196A
(zh)
*
|
2008-10-22 |
2012-07-18 |
诺沃根研究控股有限公司 |
用于诱导程序性细胞死亡的方法
|
CN102203253B
(zh)
|
2008-10-24 |
2016-04-06 |
萨雷普塔治疗公司 |
用于dmd的多外显子跳跃组合物
|
JP5603876B2
(ja)
|
2008-10-29 |
2014-10-08 |
セルジーン コーポレイション |
癌の治療に使用するためのイソインドリン化合物
|
US10463677B2
(en)
|
2008-11-07 |
2019-11-05 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
EP2373166A4
(en)
|
2008-11-15 |
2014-11-05 |
Rib X Pharmaceuticals Inc |
ANTIMICROBIAL COMPOSITIONS
|
WO2010058858A1
(ja)
|
2008-11-21 |
2010-05-27 |
ラクオリア創薬株式会社 |
5-ht2b受容体拮抗活性を有する新規ピラゾール-3-カルボキサミド誘導体
|
AU2009330355B2
(en)
|
2008-12-16 |
2016-06-30 |
Sunovion Pharmaceuticals Inc. |
Triple reuptake inhibitors and methods of their use
|
SG172219A1
(en)
|
2008-12-17 |
2011-07-28 |
Genentech Inc |
Hepatitis c virus combination therapy
|
SG10201504789RA
(en)
|
2008-12-31 |
2015-07-30 |
Sunesis Pharmaceuticals Inc |
Method Of Preparing (+)-1,4-Dihydro-7-[(3s,4s)-3methoxy-4-(Methylamino)-1-Pyrrolidinyl]-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acid
|
HUE025013T2
(hu)
|
2009-01-12 |
2016-04-28 |
Pfizer Ltd |
Szulfonamid-származékok
|
WO2010082813A1
(en)
|
2009-01-13 |
2010-07-22 |
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam |
Method of treating cancer
|
JP5719312B2
(ja)
|
2009-01-14 |
2015-05-13 |
ノヴァクタ バイオシステムズ リミティッド |
デオキシアクタガルジン誘導体
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
AU2010212183B2
(en)
|
2009-02-04 |
2014-07-10 |
Novacta Biosystems Limited |
Actagardine derivatives
|
MY160002A
(en)
|
2009-02-10 |
2017-02-15 |
Celgene Corp |
Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
|
CA2752073A1
(en)
|
2009-02-11 |
2010-08-19 |
Sunovion Pharmaceuticals Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
EP2396312A1
(en)
|
2009-02-11 |
2011-12-21 |
Celgene Corporation |
Isotopologues of lenalidomide
|
EP2400959A1
(en)
|
2009-02-27 |
2012-01-04 |
Sunesis Pharmaceuticals, Inc. |
Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
|
JP5749659B2
(ja)
|
2009-03-12 |
2015-07-15 |
ハーゼ インベストメンツ ウーゲー |
Bmpアンタゴニスト感受性が低下した骨形成タンパク質2(bmp2)変異体
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
EP2233502A1
(en)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
JP5699129B2
(ja)
*
|
2009-04-14 |
2015-04-08 |
イーライ リリー アンド カンパニー |
造血器新生物および白血病の治療のためのベンゾジアゼピン誘導体
|
JP5808739B2
(ja)
*
|
2009-05-13 |
2015-11-10 |
サイデックス・ファーマシューティカルズ・インコーポレイテッド |
プラスグレル及びシクロデキストリン誘導体を含む医薬組成物並びにその製造方法及び使用方法
|
JP5645816B2
(ja)
|
2009-05-25 |
2014-12-24 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
WO2010136940A1
(en)
|
2009-05-29 |
2010-12-02 |
Pfizer Limited |
Novel glucocorticoid receptor agonists
|
NZ596515A
(en)
|
2009-05-29 |
2014-03-28 |
Cydex Pharmaceuticals Inc |
Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
RU2011153723A
(ru)
|
2009-06-10 |
2013-07-20 |
Суновион Фармасьютикалз Инк. |
Обратные агонисты и антагонисты н3 рецепторов гистамина и способы их применения
|
EP2266563A1
(en)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
|
MX2011013080A
(es)
|
2009-06-16 |
2012-01-20 |
Pfizer |
Formas de dosis de apixaban.
|
KR20120124353A
(ko)
|
2009-06-24 |
2012-11-13 |
스티븐 에반스-프레케 |
암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
DE102009034368A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
EA201270283A1
(ru)
|
2009-08-19 |
2012-12-28 |
Рациофарм Гмбх |
Способ получения соэвапоратов и комплексы, содержащие вориконазол и циклодекстрин
|
WO2011031816A2
(en)
|
2009-09-11 |
2011-03-17 |
Sepracor Inc. |
Histamine h3 inverse agonists and antagonists and methods of use thereof
|
US20110082098A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
US8697858B2
(en)
|
2009-11-13 |
2014-04-15 |
Sarepta Therapeutics, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
WO2011063102A1
(en)
|
2009-11-19 |
2011-05-26 |
Celgene Corporation |
Apremilast for the treatment of sarcoidosis
|
WO2011064558A2
(en)
|
2009-11-30 |
2011-06-03 |
Cipla Limited |
Pharmaceutical composition
|
BR122021013836B1
(pt)
|
2009-12-04 |
2022-05-24 |
Sunovion Pharmaceuticals, Inc. |
Composto e seu uso, composição farmacêutica
|
WO2011075699A2
(en)
|
2009-12-18 |
2011-06-23 |
Sunovion Pharmaceuticals Inc. |
Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
WO2011079091A1
(en)
|
2009-12-22 |
2011-06-30 |
Celgene Corporation |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
EP3825316A1
(en)
|
2009-12-23 |
2021-05-26 |
Takeda Pharmaceutical Company Limited |
Fused heteroaromatic pyrrolidinones as syk inhibitors
|
WO2011084968A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
CA2789164A1
(en)
|
2010-02-02 |
2011-08-11 |
Novacta Biosystems Limited |
Lantibiotic salts
|
ES2730763T3
(es)
|
2010-02-11 |
2019-11-12 |
Celgene Corp |
Derivados de arilmetoxi isoindolina y composiciones que los comprenden y métodos de uso de los mismos
|
EP2539358A1
(en)
|
2010-02-25 |
2013-01-02 |
Pfizer Limited |
Peptide analogues
|
US9359398B2
(en)
|
2010-03-01 |
2016-06-07 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
US9068185B2
(en)
|
2010-03-12 |
2015-06-30 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
MX2012010367A
(es)
*
|
2010-03-12 |
2012-11-23 |
Celgene Corp |
Metodos para el tratamiento de linfomas no hodgkin que usan lenalidomida y biomarcadores de genes y proteinas como un predictor.
|
CN102946729B
(zh)
|
2010-04-07 |
2014-11-05 |
欧尼斯治疗公司 |
结晶肽环氧酮免疫蛋白酶体抑制剂
|
WO2011138751A2
(en)
|
2010-05-04 |
2011-11-10 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
EP3023496B1
(en)
|
2010-05-13 |
2020-07-29 |
Sarepta Therapeutics, Inc. |
Compounds which modulate interleukins 17 and 23 signaling activity
|
AU2011258964B2
(en)
|
2010-05-26 |
2015-04-16 |
Neurophyxia B.V. |
2-iminobiotin formulations and uses thereof
|
EP2576540B1
(en)
|
2010-05-26 |
2019-09-04 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
US8937063B2
(en)
|
2010-06-24 |
2015-01-20 |
Trustees Of Tufts College |
Niacin mimetics, and methods of use thereof
|
CN103096895B
(zh)
|
2010-06-24 |
2016-06-01 |
塔夫茨大学信托人 |
烟酸模拟物及其使用的方法
|
ES2893444T3
(es)
|
2010-06-29 |
2022-02-09 |
Merck Sharp & Dohme |
Formulaciones de posaconazol en solución intravenosa estabilizadas mediante beta-ciclodextrina sustituida
|
NL2005052C2
(en)
|
2010-07-07 |
2012-01-10 |
Caroline Haaften |
Xanthanodien for the treatment of cancer.
|
EP2590951B1
(en)
|
2010-07-09 |
2015-01-07 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
EP2590972B1
(en)
|
2010-07-09 |
2015-01-21 |
Pfizer Limited |
N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
|
CA2803118C
(en)
|
2010-07-09 |
2015-11-03 |
Pfizer Limited |
Sulfonamide derivatives as nav 1.7 inhibitors
|
ES2525581T3
(es)
|
2010-07-12 |
2014-12-26 |
Pfizer Limited |
Derivados de N-sulfonilbenzamida útiles como inhibidores del canal de sodio dependiente de voltaje
|
US9096500B2
(en)
|
2010-07-12 |
2015-08-04 |
Pfizer Limited |
Acyl sulfonamide compounds
|
WO2012007883A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
|
WO2012007869A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
WO2012007877A2
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
EP2409699B1
(en)
|
2010-07-23 |
2014-04-30 |
Combino Pharm, S.L. |
Stable compositions of voriconazole
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
ES2591355T3
(es)
|
2010-08-24 |
2016-11-28 |
Algiax Pharmaceuticals Gmbh |
Uso novedoso de leflunomida y malononitrilamidas
|
CN103154012B
(zh)
|
2010-08-24 |
2015-11-25 |
英皇创新有限公司 |
聚丙基醚亚胺的糖树状聚体
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
LT2632451T
(lt)
|
2010-10-29 |
2018-02-12 |
Algiax Pharmaceuticals Gmbh |
Malononitrilamidų panaudojimas esant neuropatiniam skausmui
|
CA2816322A1
(en)
|
2010-11-01 |
2012-05-10 |
Marshall Edwards, Inc. |
Isoflavonoid compositions and methods for the treatment of cancer
|
BR112013011991A2
(pt)
|
2010-11-15 |
2016-08-30 |
Viiv Healthcare Uk Ltd |
composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit.
|
US20140031325A1
(en)
|
2010-12-06 |
2014-01-30 |
Celgene Corporation |
Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
MX347928B
(es)
|
2011-01-10 |
2017-05-19 |
Celgene Corp |
Derivados de fenetilsulfona isoindolina y su uso.
|
ES2627788T3
(es)
|
2011-01-11 |
2017-07-31 |
Sunovion Pharmaceuticals Inc. |
Compuestos heteroarilo y procedimientos de uso de los mismos
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
US9045417B2
(en)
|
2011-01-14 |
2015-06-02 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
US10463687B2
(en)
|
2011-01-20 |
2019-11-05 |
Cornell University |
Treatments for retinal disorders
|
AU2012209184B2
(en)
|
2011-01-26 |
2017-06-15 |
Allergan, Inc. |
Androgen composition for treating an opthalmic condition
|
CN103338753A
(zh)
|
2011-01-31 |
2013-10-02 |
细胞基因公司 |
胞苷类似物的药物组合物及其使用方法
|
ES2533042T3
(es)
|
2011-02-25 |
2015-04-07 |
Takeda Pharmaceutical Company Limited |
Oxazinopteridinas y oxazinopteridinonas N-sustituidas
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
WO2012120365A1
(en)
|
2011-03-07 |
2012-09-13 |
Aurobindo Pharma Limited |
Stable pharmaceutical composition comprising ethinyl estradiol
|
DK2683708T3
(da)
|
2011-03-11 |
2018-01-29 |
Celgene Corp |
Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf
|
BR112013023280A2
(pt)
|
2011-03-11 |
2017-09-19 |
Celgene Corp |
uso de 3-(5-amino-2-metil-4-oxoquinazolina-3(4h)-il)-piperidina-2,6-diona em tratamento de doenças inflamatórias e relacionadas ao sistema imune
|
US20140038967A1
(en)
|
2011-03-17 |
2014-02-06 |
Algiax Pharmaceuticals Gmbh |
Novel use for imidazotriazinones
|
WO2012123353A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of benzofuranylsulfonates
|
AU2012236655B2
(en)
|
2011-03-28 |
2016-09-22 |
Deuterx, Llc, |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
RU2464042C1
(ru)
*
|
2011-03-31 |
2012-10-20 |
Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" |
КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
|
PE20141050A1
(es)
|
2011-04-05 |
2014-08-30 |
Pfizer Ltd |
Inhibidores de quinasa relacionados con pirrolo (2,3-d) pirimidina tropomiosina
|
WO2012138214A1
(en)
|
2011-04-08 |
2012-10-11 |
Brewster Lizzy Maritza |
Beta-guanidinopropionic acid for the treatment of hypertension
|
JP6016892B2
(ja)
|
2011-04-29 |
2016-10-26 |
セルジーン コーポレイション |
セレブロンを予測因子として使用する癌及び炎症性疾患の治療方法
|
EP2710002B1
(en)
|
2011-05-18 |
2017-03-01 |
RaQualia Pharma Inc |
Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
CA2837232A1
(en)
*
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
KR101731155B1
(ko)
|
2011-06-15 |
2017-04-27 |
신톤 비.브이. |
안정화된 보리코나졸 조성물
|
WO2012177714A1
(en)
|
2011-06-22 |
2012-12-27 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
US9513253B2
(en)
|
2011-07-11 |
2016-12-06 |
Advanced Liquid Logic, Inc. |
Droplet actuators and techniques for droplet-based enzymatic assays
|
WO2013008123A1
(en)
|
2011-07-13 |
2013-01-17 |
Pfizer Limited |
Enkephalin analogues
|
CA2839593A1
(en)
|
2011-07-15 |
2013-01-24 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
KR20140041906A
(ko)
|
2011-08-02 |
2014-04-04 |
화이자 인코포레이티드 |
암의 치료에 사용하기 위한 크리조티닙
|
EP2739274A1
(en)
|
2011-08-02 |
2014-06-11 |
Pensieve Biosciences Cyprus Limited |
Treatment of cognitive impairment
|
EP2561863A1
(en)
|
2011-08-22 |
2013-02-27 |
Farmaprojects, S.A.U. |
Pharmaceutical compositions comprising voriconazole
|
JP2014526512A
(ja)
|
2011-09-18 |
2014-10-06 |
ユーロ−セルティーク エス.エイ. |
医薬組成物
|
WO2013043985A1
(en)
|
2011-09-23 |
2013-03-28 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
PE20141682A1
(es)
|
2011-10-26 |
2014-11-14 |
Pfizer Ltd |
Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio
|
ES2748656T3
(es)
|
2011-10-28 |
2020-03-17 |
Inhibitaxin Ltd |
Derivados de piridazina útiles en terapia
|
JP6132848B2
(ja)
|
2011-12-08 |
2017-05-31 |
サレプタ セラピューティクス, インコーポレイテッド |
ヒトlmnaを標的とするオリゴヌクレオチド類似体
|
CA2857603C
(en)
|
2011-12-15 |
2016-08-02 |
Pfizer Limited |
Sulfonamide derivatives
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
WO2013096049A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
KR20140104047A
(ko)
|
2011-12-23 |
2014-08-27 |
노파르티스 아게 |
Bcl2와 결합 파트너의 상호작용을 억제하기 위한 화합물
|
US20140350014A1
(en)
|
2011-12-23 |
2014-11-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20140357666A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20140357633A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
TW201332572A
(zh)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
具有經取代的β-環糊精之藥物製劑
|
WO2013102826A1
(en)
|
2012-01-04 |
2013-07-11 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
CN104736158A
(zh)
|
2012-01-23 |
2015-06-24 |
萨奇治疗股份有限公司 |
神经活性类固醇制剂和治疗中枢神经系统障碍的方法
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
TWI573792B
(zh)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
WO2013114250A1
(en)
|
2012-02-03 |
2013-08-08 |
Pfizer Inc. |
Benziimidazole and imidazopyridine derivatives as sodium channel modulators
|
CA3132120C
(en)
|
2012-02-08 |
2023-10-24 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
TW201336527A
(zh)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
DK2814849T3
(da)
|
2012-02-15 |
2020-03-09 |
Cydex Pharmaceuticals Inc |
Fremgangsmåde til fremstilling af cyclodextrin-derivater
|
WO2013126394A1
(en)
|
2012-02-21 |
2013-08-29 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
CA2865950C
(en)
|
2012-02-28 |
2016-12-20 |
Cydex Pharmaceuticals, Inc. |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
EP2819691A1
(en)
|
2012-03-02 |
2015-01-07 |
Erasmus University Medical Center Rotterdam |
Methods for activating retrovirus in latent infected cells, and compounds for use therein
|
EP2822953B9
(en)
|
2012-03-06 |
2017-06-21 |
Pfizer Inc |
Macrocyclic derivatives for the treatment of proliferative diseases
|
US9365566B2
(en)
|
2012-03-27 |
2016-06-14 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives
|
CA2869056C
(en)
|
2012-03-30 |
2020-02-25 |
Sapiotec Gmbh |
Anthocyanidin complex
|
JP6193970B2
(ja)
|
2012-03-30 |
2017-09-06 |
ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH |
黄色ブドウ球菌(Staphylococcusaureus)に対するデルフィニジンの使用
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
AU2013257830A1
(en)
|
2012-05-11 |
2014-11-20 |
Cipla Limited |
Pharmaceutical composition
|
AU2013261129B2
(en)
|
2012-05-15 |
2016-05-12 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
AU2013261128B2
(en)
|
2012-05-15 |
2015-11-12 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
|
CN104302634B
(zh)
|
2012-05-15 |
2017-02-08 |
诺华股份有限公司 |
用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物
|
PE20210667A1
(es)
|
2012-05-15 |
2021-04-05 |
Novartis Ag |
Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
|
WO2013183985A1
(en)
|
2012-06-05 |
2013-12-12 |
Erasmus University Medical Center Rotterdam |
Method of treating cognitive impairment and compounds for use therein
|
EP2867671B1
(en)
|
2012-06-29 |
2018-10-24 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
WO2014011695A2
(en)
|
2012-07-09 |
2014-01-16 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
MX363455B
(es)
|
2012-07-18 |
2019-03-25 |
Onyx Therapeutics Inc |
Composiciones liposómicas de inhibidores de proteasoma basadas en epoxicetona.
|
EP3741372A1
(en)
|
2012-08-09 |
2020-11-25 |
Celgene Corporation |
(s)-3-[4-(4-morphlin-4-ylmethylbenzyloxy)-1- oxo-1,3-dihydro-isoindo-2-yl]piperidine-2,6-dione for use in the treatment of immune-related and inflammatory diseases
|
KR102146848B1
(ko)
|
2012-08-09 |
2020-08-21 |
셀진 코포레이션 |
3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
|
CA2878954C
(en)
|
2012-08-09 |
2020-12-08 |
Benjamin M. Cohen |
Salts and solid forms of (s)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
RU2667010C2
(ru)
|
2012-08-21 |
2018-09-13 |
Сейдж Терапьютикс, Инк. |
Способы лечения эпилепсии или эпилептического статуса
|
CA2883130A1
(en)
|
2012-08-31 |
2014-03-06 |
The General Hospital Corporation |
Biotin complexes for treatment and diagnosis of alzheimer's disease
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
EA201590535A1
(ru)
|
2012-09-10 |
2015-07-30 |
Селджин Корпорейшн |
Способы лечения локально прогрессирующего запущенного рака молочной железы
|
CA2884921A1
(en)
|
2012-09-18 |
2014-03-27 |
Ziarco Pharma Ltd |
2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
|
JP6254169B2
(ja)
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
JP2015531395A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
ピロロ[3,2−c]ピリジントロポミオシン関連キナーゼ阻害剤
|
US20150250785A1
(en)
|
2012-10-04 |
2015-09-10 |
Pfizer Limited |
Tropomyosin-Related Kinase Inhibitors
|
CA2885253A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
|
NZ707323A
(en)
|
2012-10-22 |
2018-11-30 |
Cydex Pharmaceuticals Inc |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
WO2014072882A1
(en)
|
2012-11-08 |
2014-05-15 |
Pfizer Inc. |
Heteroaromatic compounds as dopamine d1 ligands
|
SG11201502763VA
(en)
|
2012-11-08 |
2015-05-28 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EP2916869A1
(en)
|
2012-11-09 |
2015-09-16 |
Celgene Corporation |
Methods for the treatment of bone loss
|
KR102147084B1
(ko)
|
2012-11-15 |
2020-08-24 |
자피오텍 게엠베하 |
소염성 활성 물질 또는 면역 억제성 활성물질로서 델피니딘 복합제
|
US10179779B2
(en)
|
2012-11-21 |
2019-01-15 |
Raqualia Pharma Inc. |
Polymorph forms
|
JP6302480B2
(ja)
|
2012-11-29 |
2018-03-28 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
中枢神経系疾患の治療に有用なトリアゾロ−ピラジン誘導体
|
EP4335505A3
(en)
|
2012-11-30 |
2024-06-05 |
The Regents of The University of California |
Anticonvulsant activity of steroids
|
BR112015011897B1
(pt)
|
2012-12-03 |
2021-11-03 |
Pfizer Inc |
Compostos moduladores seletivos do receptor de andrógeno e seu uso
|
EP2931287B1
(de)
|
2012-12-11 |
2017-10-04 |
Sapiotec GmbH |
Delphinidin zur bekämpfung von melanomzellen
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
JP2016502858A
(ja)
|
2012-12-20 |
2016-02-01 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィを処置するための改善されたエキソンスキッピング組成物
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
JP6359560B2
(ja)
|
2012-12-31 |
2018-07-18 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
複素環式化合物及びその使用方法
|
US9540340B2
(en)
|
2013-01-14 |
2017-01-10 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
WO2014116573A1
(en)
|
2013-01-22 |
2014-07-31 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
SG11201505697VA
(en)
|
2013-02-19 |
2015-09-29 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
MX363715B
(es)
|
2013-02-21 |
2019-03-29 |
Pfizer |
Formas solidas de un inhbidor de cdk4/6 selectivo.
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
CA2902547A1
(en)
*
|
2013-03-14 |
2014-09-25 |
Allergan, Inc. |
Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process
|
EP3760720A1
(en)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
BR122020016865B1
(pt)
|
2013-03-14 |
2022-12-27 |
Sarepta Therapeutics, Inc. |
Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
|
CA2906812A1
(en)
|
2013-03-15 |
2014-09-18 |
Sarepta Therapeutics, Inc. |
Improved compositions for treating muscular dystrophy
|
EP2784083A1
(en)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
|
WO2014165482A1
(en)
|
2013-04-02 |
2014-10-09 |
Celgene Corporation |
Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers
|
EP2792360A1
(en)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
PT3013813T
(pt)
|
2013-06-27 |
2019-06-14 |
Pfizer |
Compostos heteroaromáticos e a sua utilização como ligandos de d1 de dopamina
|
CN105517541A
(zh)
|
2013-07-08 |
2016-04-20 |
艾伯维公司 |
包含阿曲生坦的稳定化药物剂型
|
GB201312737D0
(en)
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
WO2015092610A1
(en)
|
2013-12-20 |
2015-06-25 |
Pfizer Limited |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
AR099052A1
(es)
|
2014-01-09 |
2016-06-29 |
Takeda Pharmaceuticals Co |
Derivados de azaindol
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
CN103694376B
(zh)
*
|
2014-01-10 |
2016-04-13 |
凯莱英医药集团(天津)股份有限公司 |
一种制备磺丁基醚-β-环糊精的方法
|
WO2015109037A1
(en)
|
2014-01-15 |
2015-07-23 |
Deuterx, Llc |
Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JP6473457B2
(ja)
|
2014-01-17 |
2019-02-20 |
ノバルティス アーゲー |
Shp2の活性を阻害するための1−(トリアジン−3−イル/ピリダジン−3−イル)−ピペリジン/ピペラジン誘導体およびその組成物
|
WO2015107493A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
|
EP2913050A1
(de)
|
2014-02-28 |
2015-09-02 |
SapioTec GmbH |
Verfahren zur Herstellung eines Flurankomplexes
|
EP3119744B1
(en)
|
2014-03-18 |
2019-03-06 |
Algiax Pharmaceuticals GmbH |
2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
CR20160493A
(es)
|
2014-04-25 |
2016-12-16 |
Pfizer |
Compuestos heteroaromáticos y su uso como ligandos de dopamina d1
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
WO2015162516A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EP3137469B1
(en)
|
2014-04-28 |
2019-10-09 |
Pfizer Inc |
Heterocyclic compounds and their use as dopamine d1 ligands
|
WO2015166370A1
(en)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
EP3140298A1
(en)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
JP6663857B2
(ja)
|
2014-05-14 |
2020-03-13 |
ファイザー・インク |
ピラゾロピリジンおよびピラゾロピリミジン
|
HUE052692T2
(hu)
|
2014-05-15 |
2021-05-28 |
Pfizer |
6-[(4R)-4-metil-1,2-dioxido-1,2,6-tiadiazinan-2-il]izokinolin-1-karbonitril kristályos formája
|
ES2747989T3
(es)
|
2014-05-20 |
2020-03-12 |
Raqualia Pharma Inc |
Sal de derivado de benzisoxazol
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
WO2015181797A1
(en)
|
2014-05-30 |
2015-12-03 |
Pfizer Inc. |
Benzenesulfonamides useful as sodium channel inhibitors
|
KR20160147007A
(ko)
|
2014-05-30 |
2016-12-21 |
화이자 인코포레이티드 |
선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
|
CA2951497C
(en)
|
2014-06-12 |
2019-04-09 |
Pfizer Limited |
Imidazopyridazine derivatives as modulators of the gabaa receptor activity
|
PE20161552A1
(es)
|
2014-06-17 |
2017-01-11 |
Pfizer |
Compuestos de dihidroisoquinolinona sustituida
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
AU2015277554C1
(en)
|
2014-06-18 |
2018-05-31 |
Audevard |
Transdermal formulations of pergolide and uses thereof
|
EP3160486B1
(en)
|
2014-06-27 |
2020-11-18 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
TWI568365B
(zh)
*
|
2014-07-22 |
2017-02-01 |
蘇廷弘 |
抑菌複合物及其製造方法
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
ES2940302T3
(es)
|
2014-08-22 |
2023-05-05 |
Celgene Corp |
Métodos para tratar el mieloma múltiple con compuestos inmunomoduladores en combinación con anticuerpos
|
WO2016029179A1
(en)
|
2014-08-22 |
2016-02-25 |
Cydex Pharmaceuticals, Inc. |
Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
WO2016044433A2
(en)
|
2014-09-16 |
2016-03-24 |
Biopharma Works |
Metformin derivatives
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
BR112017015536B1
(pt)
|
2015-01-22 |
2021-05-18 |
Phytoplant Research S.L |
métodos de purificação de canabinoides
|
DK3050574T3
(da)
|
2015-01-28 |
2020-01-20 |
Univ Bordeaux |
Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
|
AU2016215515B2
(en)
|
2015-02-02 |
2020-04-30 |
Mei Pharma, Inc. |
Combination therapies
|
US20160228454A1
(en)
|
2015-02-06 |
2016-08-11 |
Marinus Pharmaceuticals, Inc. |
Intravenous ganaxolone formulations and methods of use in treating status epilepticus and other seizure disorders
|
KR20170119705A
(ko)
|
2015-02-24 |
2017-10-27 |
화이자 인코포레이티드 |
항암제로서 유용한 치환된 뉴클레오시드 유도체
|
CA2979527A1
(en)
|
2015-03-13 |
2016-09-22 |
Endocyte, Inc. |
Conjugates of pyrrolobenzodiazepine (pbd) prodrugs for treating disease
|
CA2980170A1
(en)
|
2015-03-19 |
2016-09-22 |
Cydex Pharmaceuticals, Inc. |
Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
NL2014614B1
(en)
|
2015-04-10 |
2017-01-25 |
Pld Biochemistry B V |
Method and means for increasing antibodies against Borrelia burgdorferi and increasing antigen of Borrelia burgdorferi.
|
WO2016195476A1
(en)
|
2015-05-29 |
2016-12-08 |
Erasmus University Medical Center Rotterdam |
Treatment of cardiac arrhythmias
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
ES2805232T3
(es)
|
2015-06-19 |
2021-02-11 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
ES2741746T3
(es)
|
2015-06-19 |
2020-02-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
ES2970117T3
(es)
|
2015-06-26 |
2024-05-27 |
Celgene Corp |
Métodos para el tratamiento de sarcoma de Kaposi o linfoma inducido por KSHV usando compuestos inmunomoduladores, y usos de biomarcadores
|
CA2991164A1
(en)
|
2015-07-02 |
2017-01-05 |
Celgene Corporation |
Combination therapy for treatment of hematological cancers and solid tumors
|
US20170007617A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences Drive |
Intravenous formulations of a late sodium current inhibitor
|
JP6832914B2
(ja)
|
2015-07-31 |
2021-02-24 |
ファイザー・インク |
Magl阻害薬としての1,1,1−トリフルオロ−3−ヒドロキシプロパン−2−イルカルバマート誘導体および1,1,1−トリフルオロ−4−ヒドロキシブタン−2−イルカルバマート誘導体
|
JP2018529715A
(ja)
|
2015-09-30 |
2018-10-11 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための方法
|
RU2018123711A
(ru)
|
2015-11-30 |
2020-01-09 |
Глэксосмитклайн Интеллекчуал Проперти (Но.2) Лимитед |
Композиции для внутривенного введения
|
CA3007595C
(en)
|
2015-12-10 |
2020-08-25 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
WO2017111179A1
(en)
|
2015-12-24 |
2017-06-29 |
Takeda Pharmaceutical Company Limited |
Cocrystal, production method thereof, and medicament containing cocrystal
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
WO2017120429A1
(en)
|
2016-01-07 |
2017-07-13 |
CS Pharmasciences, Inc. |
Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
CA3011201C
(en)
|
2016-01-15 |
2020-09-22 |
Pfizer Inc. |
6,7,8,9-tetrahydro-5h-pyrido[2,3-d]azepine dopamine d3 ligands
|
RS62097B1
(sr)
*
|
2016-02-04 |
2021-08-31 |
Czap Research And Development Llc |
Pomoćna farmaceutska sredstva sa kontrolisanim otpuštanjem i raslojeni kompleks koji uključuje ciklodekstrin
|
JP6838074B2
(ja)
|
2016-03-08 |
2021-03-03 |
セージ セラピューティクス, インコーポレイテッド |
神経刺激性ステロイド、組成物、およびその使用
|
EP3426772A4
(en)
|
2016-03-09 |
2019-08-28 |
Beijing Percans Oncology Co. Ltd. |
TUMOR CELL SUSPENSION CULTURES AND ASSOCIATED METHODS
|
CN109071496B
(zh)
*
|
2016-03-31 |
2021-07-30 |
武田药品有限公司 |
异喹啉基三唑酮复合物
|
AU2017258642B2
(en)
|
2016-04-29 |
2023-08-31 |
Sarepta Therapeutics, Inc. |
Oligonucleotide analogues targeting human LMNA
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
KR102457146B1
(ko)
|
2016-06-14 |
2022-10-19 |
노파르티스 아게 |
Shp2의 활성을 억제하기 위한 화합물 및 조성물
|
US20190262375A1
(en)
|
2016-06-30 |
2019-08-29 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
KR102500936B1
(ko)
*
|
2016-07-22 |
2023-02-16 |
에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘) |
살바이러스 화합물 및 이의 용도
|
AU2017304103A1
(en)
|
2016-07-29 |
2019-01-17 |
Pfizer Inc. |
Cyclic peptides as C5 a receptor antagonists
|
JP2019523279A
(ja)
|
2016-07-29 |
2019-08-22 |
サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. |
化合物および組成物ならびにそれらの使用
|
MX2019000980A
(es)
|
2016-07-29 |
2019-07-04 |
Sunovion Pharmaceuticals Inc |
Compuestos y composiciones y usos de los mismos.
|
EP4233861A3
(en)
|
2016-08-11 |
2023-10-11 |
Ovid Therapeutics, Inc. |
Compositions for treatment of essential tremor
|
MA45920B1
(fr)
|
2016-08-15 |
2021-08-31 |
Pfizer |
Inhibiteurs de pyridopyrimidinone cdk2/4/6
|
US10532102B2
(en)
|
2016-08-19 |
2020-01-14 |
Foresee Pharmaceuticals Co., Ltd. |
Pharmaceutical composition and methods of uses
|
AU2017313897B2
(en)
*
|
2016-08-19 |
2020-06-18 |
Foresee Pharmaceuticals Co., Ltd. |
Pharmaceutical composition and methods of uses
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
CA3040155C
(en)
|
2016-10-11 |
2024-01-16 |
Euro-Celtique S.A. |
Compound for use in the treatment of hodgkin lymphoma
|
WO2018091668A1
(en)
|
2016-11-18 |
2018-05-24 |
Aicuris Anti-Infective Cures Gmbh |
Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
CA3046801A1
(en)
|
2016-12-19 |
2018-06-28 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
EP3554552B1
(en)
|
2016-12-19 |
2022-08-17 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
PT3554553T
(pt)
|
2016-12-19 |
2022-08-04 |
Sarepta Therapeutics Inc |
Conjugados oligoméricos de salto de exão para a distrofia muscular
|
EP3558950B1
(en)
|
2016-12-20 |
2023-05-10 |
Oligomerix, Inc. |
Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
|
WO2018134695A1
(en)
|
2017-01-20 |
2018-07-26 |
Pfizer Inc. |
1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
|
SG11201906427QA
(en)
|
2017-01-23 |
2019-08-27 |
Pfizer |
Heterocyclic spiro compounds as magl inhibitors
|
WO2018140671A1
(en)
|
2017-01-27 |
2018-08-02 |
Celgene Corporation |
3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
|
JP7146782B2
(ja)
|
2017-02-16 |
2022-10-04 |
サノビオン ファーマシューティカルズ インク |
統合失調症を処置する方法
|
CN110520127B
(zh)
|
2017-03-26 |
2023-05-16 |
武田药品工业株式会社 |
作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
|
US11767520B2
(en)
|
2017-04-20 |
2023-09-26 |
Atyr Pharma, Inc. |
Compositions and methods for treating lung inflammation
|
EP3618825A4
(en)
|
2017-05-03 |
2021-01-20 |
Cydex Pharmaceuticals, Inc. |
COMPOSITION CONTAINING CYCLODEXTRIN AND BUSULFAN
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
AU2018288018C1
(en)
|
2017-06-22 |
2022-10-20 |
Curadev Pharma Limited |
Small molecule modulators of human STING
|
JP2020526501A
(ja)
*
|
2017-06-30 |
2020-08-31 |
セルジーン コーポレイション |
2−(4−クロロフェニル)−n−{[2−(2,6−ジオキソピペリジン−3−イル)−1−オキソイソインドリン−5−イル]メチル}−2,2−ジフルオロアセトアミドの組成物及び使用法
|
CN117982682A
(zh)
|
2017-07-11 |
2024-05-07 |
吉利德科学公司 |
用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
|
MX2020000523A
(es)
|
2017-08-02 |
2020-08-20 |
Sunovion Pharmaceuticals Inc |
Compuestos de isocromano y usos de los mismos.
|
JP7311514B2
(ja)
|
2017-08-30 |
2023-07-19 |
ベイジン シュエンイー ファーマサイエンシズ カンパニー, リミテッド |
インターフェロン遺伝子刺激因子調節薬としての環状ジヌクレオチド
|
CN111201223B
(zh)
|
2017-09-11 |
2024-07-09 |
克鲁松制药公司 |
SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
EP3687577A1
(en)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
US20200254002A1
(en)
|
2017-09-28 |
2020-08-13 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
US20200248178A1
(en)
|
2017-09-28 |
2020-08-06 |
Sarepta Therapeutics, Inc. |
Combination therapies for treating muscular dystrophy
|
MX2020007960A
(es)
|
2018-01-29 |
2020-09-24 |
Phytoplant Res S L |
Metodos para purificar cannabinoides usando cromatografia liquido-liquido.
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
US10538542B2
(en)
|
2018-03-15 |
2020-01-21 |
Pfizer Inc. |
Cyclopentane-based modulators of STING (stimulator of interferon genes)
|
SG11202009992VA
(en)
|
2018-04-26 |
2020-11-27 |
Pfizer |
2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
CN112218627B
(zh)
|
2018-05-30 |
2024-04-16 |
康维尔特制药有限公司 |
前药及其在医学上的应用
|
EA202092974A1
(ru)
|
2018-06-01 |
2021-04-09 |
Байер Кропсайенс Лп |
Стабилизированная фунгицидная композиция, содержащая циклодекстрин
|
EP4219717A3
(en)
|
2018-06-13 |
2023-12-20 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomers for muscular dystrophy
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
BR112021000109A2
(pt)
|
2018-07-19 |
2021-03-30 |
Pfizer Inc. |
Compostos espiro heterocíclicos como inibidores de magl
|
TW202020153A
(zh)
|
2018-07-27 |
2020-06-01 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
CR20210284A
(es)
|
2018-11-29 |
2021-07-09 |
Pfizer |
Pirazoles como modulares de hemoglobina
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
AU2019397461A1
(en)
|
2018-12-13 |
2021-07-29 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
EP3906263A4
(en)
|
2019-01-03 |
2022-08-31 |
Underdog Pharmaceuticals, Inc. |
CYCLODEXTRIN DIMERS, THEIR COMPOSITIONS AND USES
|
CA3123718A1
(en)
|
2019-01-04 |
2020-07-09 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
EP3914597A1
(en)
|
2019-01-23 |
2021-12-01 |
Pfizer Inc. |
Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
|
CA3128155C
(en)
|
2019-01-31 |
2023-09-19 |
Pfizer Inc. |
3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
|
CN113395958A
(zh)
|
2019-02-01 |
2021-09-14 |
H.隆德贝克有限公司 |
基本上无10-溴-卡马西平的可注射卡马西平组合物
|
US11136304B2
(en)
|
2019-03-14 |
2021-10-05 |
Sunovion Pharmaceuticals Inc. |
Salts of a heterocyclic compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof
|
WO2020198053A1
(en)
|
2019-03-22 |
2020-10-01 |
Takeda Pharmaceutical Company Limited |
2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
|
WO2020198268A1
(en)
|
2019-03-28 |
2020-10-01 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy with casimersen
|
US20220193246A1
(en)
|
2019-04-18 |
2022-06-23 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
MA55804A
(fr)
|
2019-04-29 |
2022-04-06 |
Solent Therapeutics Llc |
Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
|
EP3987029A1
(en)
|
2019-06-19 |
2022-04-27 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
CA3147407A1
(en)
|
2019-07-25 |
2021-01-28 |
Curadev Pharma Pvt. Ltd. |
Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
|
WO2021026124A1
(en)
|
2019-08-05 |
2021-02-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treatment of status epilepticus
|
CA3149914A1
(en)
|
2019-08-06 |
2021-02-11 |
L.E.A.F. Holdings Group Llc |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
EP4031552A1
(en)
|
2019-09-16 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Azole-fused pyridazin-3(2h)-one derivatives
|
GEP20237572B
(en)
|
2019-09-25 |
2023-11-27 |
Pfizer |
Polyheterocyclic modulators of sting (stimulator of interferon genes)
|
US20210145816A1
(en)
|
2019-11-15 |
2021-05-20 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
|
WO2021113212A1
(en)
|
2019-12-02 |
2021-06-10 |
Celgene Corporation |
Therapy for the treatment of cancer
|
EP4072559A4
(en)
|
2019-12-06 |
2023-06-21 |
Marinus Pharmaceuticals, Inc. |
GANAXOLONE FOR USE IN THE TREATMENT OF TUBEROUS SCLEROSIS COMPLEX
|
CN115151304A
(zh)
|
2020-02-12 |
2022-10-04 |
库拉德夫制药私人有限公司 |
小分子干扰素基因刺激因子(sting)拮抗剂
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
AU2021265578B2
(en)
|
2020-05-01 |
2024-03-28 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
PE20231375A1
(es)
|
2020-05-04 |
2023-09-07 |
Takeda Pharmaceuticals Co |
Derivados de n-(piperidin-4-il)benzamida de accion luminal
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
WO2022013691A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorph of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
|
WO2022013692A1
(en)
|
2020-07-15 |
2022-01-20 |
Pfizer Inc. |
Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
MX2023011633A
(es)
|
2021-03-31 |
2023-12-15 |
Sevenless Therapeutics Ltd |
Inhibidores de sos1 e inhibidores de ras para su uso en el tratamiento del dolor.
|
WO2022214869A2
(en)
|
2021-04-07 |
2022-10-13 |
Lifearc |
Ulk1/2 inhibitors and their use thereof
|
MX2023015139A
(es)
|
2021-06-26 |
2024-01-22 |
Array Biopharma Inc |
Inhibidores de mutacion de her2.
|
WO2023015240A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Tricyclic fused pyrimidine compounds for use as her2 inhibitors
|
AU2022326885A1
(en)
|
2021-08-11 |
2024-02-15 |
Curadev Pharma Pvt. Ltd. |
Small molecule urea derivatives as sting antagonists
|
WO2023017451A1
(en)
|
2021-08-11 |
2023-02-16 |
Curadev Pharma Pvt. Ltd. |
Small molecule sting antagonists
|
EP4162933A1
(en)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Compound for treating non-alcoholic fatty liver disease and related diseases
|
CN118401527A
(zh)
|
2021-12-01 |
2024-07-26 |
国家公共部门基金会卡洛斯三世国家癌症研究中心(F.S.P.Cnio) |
化合物
|
WO2023178230A1
(en)
|
2022-03-17 |
2023-09-21 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidate morpholino oligomer conjugates
|
WO2023187677A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
AR129012A1
(es)
|
2022-04-07 |
2024-07-03 |
Takeda Pharmaceuticals Co |
Derivados de piridazina fusionados
|
WO2024023727A1
(en)
|
2022-07-29 |
2024-02-01 |
Pfizer Inc. |
Novel acc inhibitors
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
WO2024073570A1
(en)
|
2022-09-28 |
2024-04-04 |
Altos Labs, Inc. |
Expression of regeneration factors in aged/senescent cells
|
WO2024074827A1
(en)
|
2022-10-05 |
2024-04-11 |
Sevenless Therapeutics Limited |
New treatments for pain
|
WO2024105363A1
(en)
|
2022-11-15 |
2024-05-23 |
Curadev Pharma Ltd |
Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1
|
WO2024145608A2
(en)
|
2022-12-30 |
2024-07-04 |
Cornell University |
Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
|
WO2024157205A1
(en)
|
2023-01-26 |
2024-08-02 |
Takeda Pharmaceutical Company Limited |
1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
|